Chelsea Therapeutics is committed to developing novel therapeutic agents that address disease states that correspond to significant unmet medical need. Droxidopa is the lead investigational product candidate in our pipeline. It is in Phase III development for the treatment of symptomatic neurogenic orthostatic hypotension (neurogenic OH or nOH) in patients with underlying primary autonomic failure (Parkinson’s disease, multiple systems atrophy, and pure autonomic failure), dopamine-β-hydroxylase deficiency, and non-diabetic autonomic neuropathy. We plan to further evaluate droxidopa for potential use in additional indications where norepinephrine is believed to play a role. Our pipeline also includes a library of metabolically inert antifolate medications, including a clinical-stage product, CH-4051, for the treatment of rheumatoid arthritis and other autoimmune diseases.